Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

An antimicrobial peptide of the cathelicidin family that provides innate immune defense by killing pathogens and modulating inflammation and wound healing.

Quick Stats
Studies 2230
Trials 95
Formula C205H340N60O53
Clear All
Utility 1
pubmed Mar 27, 2012

[Post-therapeutic change of cathelicidin LL-37 in asthmatics of different inflammatory phenotypes].

Liang. Zhen-yu ZY; Zhao. Hai-jin HJ; Lü. Yan-hua YH; Dong. Hang-ming HM; Liu. Lai-yu LY; Zhu. S...

A small study looked at how levels of the natural peptide LL‑37 change in people with asthma after a month of inhaled steroid/bronchodilator treatment. Overall, LL‑37 went up in the blood and sputum of patients with eosinophilic (allergy‑driven) asthma, but not in those with non‑eosinophilic asthma. The rise didn’t clearly link to better lung function, so it’s unclear if this matters for health or performance.

Utility 1
pubmed 2014

Cathelicidin LL-37 in bronchoalveolar lavage and epithelial lining fluids from healthy individuals and sarcoidosis patients.

Golec. M M; Reichel. C C; Lemieszek. M M; Buczkowski. J J; Mackiewicz. B B; Skórska. C C; Dutki...

The study measured the natural antimicrobial peptide LL-37 in lung fluids of people with sarcoidosis, a lung disease, and found higher levels compared to healthy volunteers. This suggests LL-37 may be involved in the disease process, but the research does not test any treatments or give guidance on using LL-37 for health improvement.

pubmed Nov 26, 2025

Inflammatory and neuroimmune imbalance in diabetic incontinence: insights from serum biomarker profiling.

Albaz. Ali Can AC; Kosova. Funda F; Temeltaş. Gökhan G; Üçer. Oktay O; Müe...

A study measured several blood proteins, including the antimicrobial peptide LL‑37, in people with diabetes‑related urinary leakage, people with leakage but no diabetes, and healthy volunteers. Only one marker, a lipid‑peroxidation product called 4‑HNE, was lower in the diabetic group; LL‑37 and the other proteins showed no meaningful differences.

pubmed Oct 4, 2024

Distribution of Immunomodulation, Protection and Regeneration Factors in Cleft-Affected Bone and Cartilage.

Vaivads. Mārtiņš M; Pilmane. Māra M

The study looked at how several proteins, including the antimicrobial peptide LL‑37, are present in bone and cartilage tissue from people with facial clefts. It found some changes in stress‑related proteins and collagen, but it doesn’t tell us how to use LL‑37 or any of the other proteins to improve health, performance, or longevity.

pubmed Jul 11, 2025

Phage-Encoded Virulence Factor, Gp05, Alters Membrane Phospholipids and Reduces Antimicrobial Susceptibility in Methicillin-Resistant Staphylococcus aureus.

Li. Yi Y; Mishra. Nagendra N NN; Chen. Liang L; Manna. Adhar C AC; Cheung. Ambrose L AL; Proctor. Ri...

The study shows that a virus‑derived protein called Gp05 helps MRSA bacteria change their membrane fats, making them harder for the body’s natural antibiotic peptide LL‑37 and for drugs like vancomycin to kill. Removing Gp05 flips the membrane back, so the bacteria become more vulnerable to LL‑37, immune cells, and antibiotics.

pubmed Feb 11, 2025

Human antimicrobial/host defense peptide LL-37 may prevent the spread of a local infection through multiple mechanisms: an update.

Svensson. Daniel D; Nilsson. Bengt-Olof BO

LL-37 is a natural protein in our bodies that can kill a wide range of bacteria and some viruses. It also talks to the immune system, sometimes turning it on and sometimes turning it off. When it builds up to fairly high levels (around 1‑10 micromolar) it can start killing human cells, especially those that are already infected, but at very high levels (like 300 micromolar in psoriasis) it may also damage healthy tissue. The peptide’s actions depend a lot on where and how much of it is present.

pubmed Mar 18, 2024

Tumor Exosomal ENPP1 Hydrolyzes cGAMP to Inhibit cGAS-STING Signaling.

An. Yu Y; Zhu. Jinchao J; Xie. Qihui Q; Feng. Jianzhou J; Gong. Yanli Y; Fan. Qian Q; Cao. Jiao J; H...

Researchers found that tiny particles released by tumors (exosomes) contain an enzyme called ENPP1, which can break down a signaling molecule called cGAMP—even when cGAMP is carried by the peptide LL-37. By destroying cGAMP, these exosomes dampen the immune system's ability to detect and fight cancer cells, and they also reduce the presence of immune‑fighting T cells in tumors. This study is mainly about how cancers hide from the immune system, not about any health‑boosting use of LL‑37 for everyday people.

pubmed Dec 25, 2023

Local Defense Factors in Cleft-Affected Palate in Children before and during Milk Dentition Age: A Pilot Study.

Ozola. Laura L; Pilmane. Mara M

This study looked at a tiny group of kids with cleft palates and measured natural antimicrobial proteins like LL‑37 in their mouth tissue. It found lower levels of some defense proteins (HBD‑3, HBD‑4) and some relationships between these proteins, but it doesn’t tell you how to use LL‑37 or any other peptide for health or performance.

pubmed Sep 28, 2023

The MprF homolog LysX synthesizes lysyl-diacylglycerol contributing to antibiotic resistance and virulence.

Gill. Cameron P CP; Phan. Christopher C; Platt. Vivien V; Worrell. Danielle D; Andl. Thomas T; Roy....

The study shows that a bacterial protein called LysX adds a lysine molecule to a lipid (Lys‑DAG), which makes the bacteria much more resistant to the human antimicrobial peptide LL‑37 and other antibiotics, and also makes them more virulent. Deleting the LysX gene makes the bacteria more vulnerable and less able to cause infection.

pubmed Dec 8, 2022

LL-37 as a Powerful Molecular Tool for Boosting the Performance of Ex Vivo-Produced Human Dendritic Cells for Cancer Immunotherapy.

Stakheev. Dmitry D; Taborska. Pavla P; Kalkusova. Katerina K; Bartunkova. Jirina J; Smrz. Daniel D

The study shows that adding the peptide LL‑37 while making immune cells (dendritic cells) in a lab can make those cells better at activating cancer‑killing T‑cells, but this is a complex cell‑culture technique not usable outside specialized research labs.

pubmed Jul 2, 2023

Antimicrobial Peptides and Interleukins in Cleft Soft Palate.

Deņisova. Arina A; Pilmane. Māra M; Kažoka. Dzintra D

This study looked at tiny proteins that fight germs and control inflammation in the soft palate of kids with a cleft palate. It found that some antimicrobial proteins (like HBD‑2 and HBD‑4) and an anti‑inflammatory signal (IL‑10) were higher in the affected tissue, while the levels of LL‑37 varied a lot. The researchers think these proteins work together to protect the tissue, but the work doesn’t tell you how to use LL‑37 for health or performance.

pubmed Apr 28, 2022

Layer-by-Layer Nanoarchitectonics Using Protein-Polyelectrolyte Complexes toward a Generalizable Tool for Protein Surface Immobilization.

Vranckx. Cédric C; Lambricht. Laure L; Préat. Véronique V; Cornu. Olivier O; Dupont-G...

Scientists figured out a way to stick proteins like the antimicrobial peptide LL‑37 onto surfaces by first pairing them with charged polymers, then layering them. This makes thicker, more water‑rich films, but the work is about material science, not about how to use LL‑37 for health.

pubmed May 21, 2022

Gene essentiality profiling reveals a novel determinant of stresses preventing protein aggregation in <i>Salmonella</i>.

Wang. Zuoqiang Z; Zhu. Siqi S; Li. Congcong C; Lyu. Lin L; Yu. Jingchen J; Wang. Danni D; Xu. Zhihon...

Scientists mapped which Salmonella genes help the bacteria survive many different stresses, including the human antimicrobial peptide LL‑37. They found a handful of core genes needed everywhere and discovered a new gene, yheM, that prevents protein clumping, plus an sRNA (STnc2080) that the bacteria need to resist LL‑37. The work is about bacterial survival, not about using LL‑37 in humans.

pubmed Jan 1, 2022

The effects of photobiomodulation therapy on inflammatory mediators, immune infiltration, and angiogenesis in a mouse model of rosacea.

Wu. Shuwei S; Su. Yaoxi Y; Wang. Lian L; Sun. Bensen B; Jiang. Xian X

Rosacea is a chronic skin disorder with increasing prevalence and challenging management. Photobiomodulation therapy (PBMT) may be a promising adjuvant treatment for rosacea. This study investigated the efficacy of PBMT for the treatment of rosacea lesions in a well-established mouse model using a combination of wavelengths at 590 and 830 nm. Female BALB/c mice were randomized into three groups, namely, a negative control (NC) group, a model control (MC) group, and a PBMT group. Mice were injected with LL-37 or normal saline for construction of the model and NCs, respectively. Mice in the PBMT group were administered PBMT at wavelengths of 590 nm (25 mW) and 830 nm (50 mW). The severity of erythema, inflammatory cell counts, the expression of key inflammatory mediators, and the degree of angiogenesis and immune cell infiltration of the skin lesions were evaluated by hematoxylin and eosin (H&amp;E) staining, immunohistochemistry, and immunofluorescence staining. PBMT significantly decreased the erythema scores and inflammatory cell infiltration of rosacea lesions in mice. Further studies revealed that PBMT downregulated the increased expression of inflammatory mediators (S100A9 and p65) and angiogenesis markers (CD31), and attenuated the dysregulation of immune cell infiltration [including neutrophils, regulatory T cells (Treg cells), &#x3b3;&#x3b4; T cells, and macrophages] in mice with rosacea. This investigation suggested that PBMT can improve the rosacea condition by regulating key inflammatory mediators and dysregulating immune infiltration and angiogenesis.